Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells

Authors: Aktan Alpsoy, Ufuk Gündüz

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Success of chemotherapy is generally impaired by multidrug resistance, intrinsic resistance, or acquired resistance to functionally and structurally irrelevant drugs. Multidrug resistance emerges via distinct mechanisms: increased drug export, decreased drug internalization, dysfunctional apoptotic machinery, increased DNA damage repair, altered cell cycle regulation, and increased drug detoxification. Several reports demonstrated that multidrug resistance is a multifaceted problem such that multidrug resistance correlates with increased aggressiveness and metastatic potential. Here, we tested the involvement of protein kinase D2, a serine/threonine kinase that was previously implicated in proliferation, drug resistance, and motility in doxorubicin-resistant MCF7 (MCF7/DOX) cell line, which served as an in vitro model for drug resistance and invasiveness. We showed that basal level activity of protein kinase D2 (PKD2) was higher in MCF7/DOX cells than parental MCF7 cells. To elucidate the roles of PKD2 MCF7/DOX, PKD2 expression was reduced via small interfering RNA (siRNA)-mediated knockdown. Results showed that acquired resistance of MCF7/DOX to doxorubicin was not affected by PKD2 silencing, while motility of MCF7/DOX cells was reduced. The results implied that PKD2 silencing might inhibit migration of MCF7/DOX cells without affecting chemoresistance significantly.
Appendix
Available only for authorised users
Literature
1.
2.
Gillet J, Gottesman MM. In: Zhou J, editor. Multi-drug resistance in cancer. Totowa: Humana; 2010. p. 596.
3.
Baguley BC. Multidrug resistance in cancer. In: Zhou J, editor. Multi-drug resistance in cancer. Humana; 2010. page 4–6.
4.
Lage H. Review an overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci. 2008;65:3145–67.CrossRefPubMed
5.
Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother. 2011;65:40–5.CrossRefPubMed
6.
Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417:679–85. Elsevier Inc.CrossRefPubMed
7.
Saxena M, Stephens MA, Pathak H, Rangarajan A, Nature Publishing Group. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179.CrossRefPubMedPubMedCentral
8.
Lamouille S, Xu J, Derynck R, Nature Publishing Group. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.CrossRefPubMedPubMedCentral
9.
Li Q-Q, Xu J-D, Wang W-J, Cao X-X, Chen Q, Tang F, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009;15:2657–65.CrossRefPubMed
10.
11.
Storz P. In: Chatterjee M, Kashfi K, editors. Cell signaling & molecular targets in cancer. New York: Springer; 2012. p. 245–71.CrossRef
12.
Jackson LN, Li J, Chen LA, Townsend CM, Evers BM. Overexpression of wild-type PKD2 leads to increased proliferation and invasion of BON endocrine cells. Biochem Biophys Res Commun. 2006;348:945–9.CrossRefPubMedPubMedCentral
13.
Huck B, Duss S, Hausser A, Olayioye MA. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem. 2014;289:3138–47.CrossRefPubMed
14.
Liu P, Scharenberg AM, Cantrell DA, Matthews SA. Protein kinase D enzymes are dispensable for proliferation, survival and antigen receptor-regulated NFkappaB activity in vertebrate B-cells. FEBS Lett. 2007;581:1377–82.CrossRefPubMedPubMedCentral
15.
Hao Q, Wang L, Zhao ZJ, Tang H. Identification of protein kinase D2 as a pivotal regulator of endothelial cell proliferation, migration, and angiogenesis. J Biol Chem. 2009;284:799–806.CrossRefPubMed
16.
Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, et al. Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol. 2010;10:5.CrossRefPubMedPubMedCentral
17.
Chen J, Deng F, Singh SV, Wang QJ. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 2008;68:3844–53.CrossRefPubMed
18.
Hao Q, McKenzie R, Gan H, Tang H. Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells. Anticancer Res. 2013;33:393–9.PubMed
19.
Karam M, Legay C, Auclair C, Ricort J-M. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp Cell Res. 2012;318:558–69. Elsevier Inc.CrossRefPubMed
20.
21.
22.
Armacki M, Joodi G, Nimmagadda SC, de Kimpe L, Pusapati GV, Vandoninck S, et al. A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis. Oncogene. 2014;33:1167–80. Macmillan Publishers Limited.CrossRefPubMed
23.
Chen J, Lu L, Feng Y, Wang H, Dai L, Li Y, et al. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett. 2011;300:48–56. Elsevier Ireland Ltd.CrossRefPubMed
24.
Xiao M, Liu Y, Zou F. Sensitization of human colon cancer cells to sodium butyrate-induced apoptosis by modulation of sphingosine kinase 2 and protein kinase D. Exp Cell Res. 2012;318:43–52. Elsevier Inc.CrossRefPubMed
25.
Eiseler T, Döppler H, Yan IK, Goodison S, Storz P. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res. 2009;11:R13.CrossRefPubMedPubMedCentral
26.
Peterburs P, Heering J, Link G, Pfizenmaier K, Olayioye MA, Hausser A. Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res. 2009;69:5634–8.CrossRefPubMed
27.
Döppler H, Bastea LI, Borges S, Spratley SJ, Pearce SE, Storz P. Protein kinase d isoforms differentially modulate cofilin-driven directed cell migration. PLoS One. 2014;9:e98090.CrossRefPubMedPubMedCentral
28.
Bernhart E, Damm S, Wintersperger A, DeVaney T, Zimmer A, Raynham T, et al. Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro. Exp Cell Res. 2013;319:2037–48. Elsevier.CrossRefPubMedPubMedCentral
29.
Borges S, Storz P. Protein kinase D isoforms: new targets for therapy in invasive breast cancers? Expert Rev Anticancer Ther. 2013;13:895–8.CrossRefPubMed
30.
Kars MD, Iseri OD, Gündüz U, Ural AU, Arpaci F, Molnár J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res. 2006;26:4559–68.PubMed
31.
Tezcan O, Gündüz U. Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells. Biomed Pharmacother. 2014;68:357–64.CrossRefPubMed
32.
Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 2010;38:D792–9.CrossRefPubMed
33.
Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Häcker S, et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene. 2012;31:4677–88.CrossRefPubMed
34.
Kaplan E, Gündüz U. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance. Biomed Pharmacother. 2012;66:29–35.CrossRefPubMed
35.
Sturany S, Van Lint J, Muller F, Wilda M, Hameister H, Hocker M, et al. Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem. 2001;276:3310–8.CrossRefPubMed
36.
Dönmez Y, Gündüz U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother. 2011;65:85–9.CrossRefPubMed
37.
38.
Du C, Zhang C, Hassan S, Biswas MHU, Balaji KC. Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res. 2010;70:7810–9.CrossRefPubMed
39.
Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP, et al. E-cadherin phosphorylation by protein kinase D1/protein kinase C μ is associated with altered cellular aggregation and motility in prostate cancer is associated with altered cellular aggregation and motility in prostate. Cancer. 2005;483–92.
40.
Wille C, Köhler C, Armacki M, Jamali A, Gössele U, Pfizenmaier K, et al. Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Mol Biol Cell. 2014;25:324–36.CrossRefPubMedPubMedCentral
41.
42.
Rogers KMA, Thomas M, Galligan L, Wilson TR, Allen WL, Sakai H, et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther. 2007;6:1544–51.CrossRefPubMed
43.
Trauzold A, Schmiedel S, Sipos B, Wermann H, Westphal S, Röder C, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene. 2003;22:8939–47.CrossRefPubMed
44.
Armacki M. Identification and characterization of PKD2 substrates -CIB1a as a substrate for PKD2 [dissertation]. Ulm: Universitätsklinikum Ulm; 2010.
45.
Christoforides C, Rainero E, Brown KK, Norman JC, Toker A. PKD controls αvβ3 integrin recycling and tumor cell invasive migration through its substrate Rabaptin-5. Dev Cell. 2012;23:560–72. Elsevier Inc.CrossRefPubMedPubMedCentral
46.
Ziegler S, Eiseler T, Scholz R-P, Beck A, Link G, Hausser A. A novel protein kinase D phosphorylation site in the tumor suppressor Rab interactor 1 is critical for coordination of cell migration. Mol Biol Cell. 2011;22:570–80.CrossRefPubMedPubMedCentral
Metadata
Title
Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells
Authors
Aktan Alpsoy
Ufuk Gündüz
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3081-3

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients

Research Article

Overexpression of CUGBP1 is associated with the progression of non-small cell lung cancer

Research Article

miR-145 inhibits invasion and metastasis by directly targeting Smad3 in nasopharyngeal cancer

Research Article

Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer

Research Article

Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression

Research Article

Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits